6-巯基嘌呤、长春新碱、甲氨蝶呤和泼尼松联合用于耐药或复发的急性非淋巴细胞白血病的治疗
Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia.
作者信息
Leone G, Pagano L, Marra R, Landolfi R, Cudillo L, Storti S, Mango G, Alfano G, D'Onofrio G
出版信息
Cancer Treat Rep. 1987 Jul-Aug;71(7-8):751-3.
Twenty-six adults with acute nonlymphoid leukemia (ANLL) relapsed or resistant after first-choice chemotherapy including cytarabine and/or anthracyclines were treated with a modified POMP (6-mercaptopurine, vincristine, methotrexate, and prednisone) combination. Complete remission (CR) was achieved in five of eight resistant patients (62%) and in nine of 18 relapsed patients (50%). Intermittent cycles of chemotherapy including daunorubicin, cytarabine, 6-thioguanine, and etoposide were then administered. In the resistant group CR lasted from 11 to 126 weeks (median, 86), with two patients remaining in CR 126 and 108 weeks after remission induction; in relapsed patients, CR lasted from 9 to 50 weeks (median, 31).
26例成人急性非淋巴细胞白血病（ANLL）患者在接受包括阿糖胞苷和/或蒽环类药物的一线化疗后复发或耐药，接受了改良的POMP（6-巯基嘌呤、长春新碱、甲氨蝶呤和泼尼松）联合方案治疗。8例耐药患者中有5例（62%）达到完全缓解（CR），18例复发患者中有9例（50%）达到CR。随后给予包括柔红霉素、阿糖胞苷、6-硫鸟嘌呤和依托泊苷的间歇化疗周期。在耐药组中，CR持续11至126周（中位数，86周），2例患者在缓解诱导后126周和108周仍处于CR状态；在复发患者中，CR持续9至50周（中位数，31周）。
Zotero 插件